Withdrawal From the Study
The rate of premature discontinuation of treatment for any reason other than relapse did not significantly differ among the three groups: 15.2%, 20.8%, and 24.0% in the 4-week, 26-week, and no-dose-reduction groups, respectively (χ2=3.16, df=2, p=0.21). The reasons for early discontinuation across the three groups were similar (Figure 1).